Vincenzo Mazzaferro
0000-0002-4013-8085
Publication & Citation Trends
Publications
0 total
Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET)
Cited by 3
Semantic Scholar
158P Atezolizumab plus bevacizumab as first-line therapy in unresectable HCC: Final analysis from phase IIIb AMETHISTA study
Cited by 0
Semantic Scholar
337P Ivosidenib for IDH1-mutant intrahepatic cholangiocarcinoma: Insights from a multicenter real-world study
Cited by 0
Semantic Scholar
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial
Cited by 16
Semantic Scholar
Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter, observational PANCAKE study
Cited by 0
Semantic Scholar
Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study OA
Cited by 4
Semantic Scholar
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO. OA
Cited by 73
Semantic Scholar
1437 Analysis by treatment period and liver function in EMERALD-1: a phase 3 study of durvalumab ± bevacizumab + TACE in participants with embolization-eligible unresectable hepatocellular carcinoma OA
Cited by 0
Semantic Scholar
423P Multicentre, multi-cohort, single-arm phase II trial of tremelimumab and durvalumab as neoadjuvant or definitive treatment of patients (pts) with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC): The INFINITY study
Cited by 1
Semantic Scholar
166P Outcomes by baseline liver function in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) with or without bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC) OA
Cited by 1
Semantic Scholar
Research Topics
Hepatocellular Carcinoma Treatment and Prognosis
(326)
Organ Transplantation Techniques and Outcomes
(163)
Liver Disease Diagnosis and Treatment
(129)
Cholangiocarcinoma and Gallbladder Cancer Studies
(126)
Liver Disease and Transplantation
(91)
Affiliations
Dokkyo University
Goethe University Frankfurt
University of Rome Tor Vergata
United States Department of Veterans Affairs
Mount Sinai Hospital
External Profiles
Continue on JournalsHub
Put what you just read into practice with these free tools.